India faces rising severe obesity. Experts discuss how GLP-1 and dual GIP/GLP-1 medications, combined with lifestyle and ...
Fatty liver disease is becoming increasingly common, yet many people still underestimate how serious it can be. Because the condition often develops quietly and without noticeable symptoms in its ...
A case of a 45-year-old construction worker with a history of intravenous drug use, homelessness, and occasional alcohol and tobacco use.
Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...
Health and Me on MSN
Breaking 8 fatty liver myths that are ignored easily
Fatty liver disease is becoming increasingly common, yet many people still misunderstand what causes it and who is at risk. Because the condition often develops silently, it is easy to ignore early ...
Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...
CRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology?focused biopharmaceutical company and majority ...
Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne Pivotal dose participants exceeded external controls across functional ...
This report describes a female patient in her 60s with an immune-mediated necrotising myopathy (IMNM) occurring after semaglutide use. She was found to have progressive dysphagia, dysphonia, proximal ...
SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration and improvements in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results